Morris A. Blajchman
#131,416
Most Influential Person Now
Morris A. Blajchman's AcademicInfluence.com Rankings
Morris A. Blajchmanphilosophy Degrees
Philosophy
#6394
World Rank
#9427
Historical Rank
Logic
#3569
World Rank
#4755
Historical Rank

Download Badge
Philosophy
Why Is Morris A. Blajchman Influential?
(Suggest an Edit or Addition)Morris A. Blajchman's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. (1999) (4305)
- A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. (2008) (1070)
- Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? (2001) (610)
- Transfusion-related immunomodulation (TRIM): an update. (2007) (582)
- Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. (2009) (558)
- Age of transfused blood in critically ill adults. (2015) (508)
- Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? (2001) (417)
- The Premature Infants in Need of Transfusion (PINT) study: a randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants. (2006) (404)
- Effects of red-cell storage duration on patients undergoing cardiac surgery. (2015) (402)
- Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial. (2012) (400)
- Histocompatibility (HL-A) Antigens, Lymphocytotoxic Antibodies and Tissue Antibodies in Patients with Diabetes Mellitus (1973) (397)
- Proceedings of a consensus conference: towards an understanding of TRALI. (2005) (373)
- Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. (2003) (367)
- Does transfusion practice affect mortality in critically ill patients? Transfusion Requirements in Critical Care (TRICC) Investigators and the Canadian Critical Care Trials Group. (1997) (345)
- Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine. (2003) (263)
- Inhibition of Injury Induced Thromboatherosclerotic Lesions by Anti-Platelet Serum in Rabbits (1976) (242)
- Biologic effects of leukocytes present in transfused cellular blood products (1994) (231)
- Blood product-associated bacterial sepsis. (1991) (231)
- A Canadian survey of transfusion practices in critically ill patients. Transfusion Requirements in Critical Care Investigators and the Canadian Critical Care Trials Group. (1998) (186)
- A randomized controlled trial comparing the frequency of acute reactions to plasma‐removed platelets and prestorage WBC‐reduced platelets (2002) (186)
- Immunomodulation and Blood Transfusion (2002) (179)
- Blood Still Kills: Six Strategies to Further Reduce Allogeneic Blood Transfusion-Related Mortality (2010) (171)
- Bacterial detection of platelets: current problems and possible resolutions. (2005) (168)
- Allogeneic blood transfusions, immunomodulation, and postoperative bacterial infection: Do we have the answers yet? (1997) (165)
- Transfusion requirements in critical care : a pilot study (1995) (157)
- Improving the bacteriological safety of platelet transfusions. (2004) (154)
- Do blood transfusions improve outcomes related to mechanical ventilation? (2001) (153)
- The Age of Blood Evaluation (ABLE) randomized controlled trial: study design. (2011) (146)
- Clinical review: Canadian National Advisory Committee on Blood and Blood Products - Massive Transfusion Consensus Conference 2011: report of the panel (2011) (138)
- The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. (1987) (135)
- Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. (1992) (133)
- Antithrombin III Mutation Database: First Update (1993) (131)
- Universal WBC reduction:the case for and against (2001) (127)
- Effect of the Factor V Leiden Mutation on the Clinical Expression of Severe Hemophilia A (2000) (123)
- Variation in red cell transfusion practice in the intensive care unit: a multicentre cohort study (1999) (121)
- Rifampicin-induced Immune Thrombocytopenia (1970) (118)
- The continuing risk of transfusion-transmitted infections. (2006) (116)
- Effects of Unfractionated Heparin, Dermatan Sulfate and Low Molecular Weight Heparin on Vessel Wall Permeability in Rabbits a (1989) (115)
- The contribution of the haematocrit to thrombocytopenic bleeding in experimental animals (1994) (109)
- Clinical outcomes following institution of universal leukoreduction of blood transfusions for premature infants. (2003) (109)
- Neurodevelopmental Outcome of Extremely Low Birth Weight Infants Randomly Assigned to Restrictive or Liberal Hemoglobin Thresholds for Blood Transfusion (2009) (108)
- Hemostatic function, survival, and membrane glycoprotein changes in young versus old rabbit platelets. (1981) (104)
- Shortening of the bleeding time in rabbits by hydrocortisone caused by inhibition of prostacyclin generation by the vessel wall. (1979) (103)
- Proceedings of a Consensus Conference: Pathogen Inactivation—Making Decisions About New Technologies☆ (2007) (102)
- Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. (1984) (101)
- The clinical benefits of the leukoreduction of blood products. (2006) (98)
- Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. (1989) (97)
- BACTERIAL CONTAMINATION OF CELLULAR BLOOD COMPONENTS (1994) (97)
- Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment. (2010) (96)
- Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. (2009) (94)
- Transfusion requirements in critical care. A pilot study. Canadian Critical Care Trials Group. (1995) (92)
- Allogeneic Blood Transfusion-Induced Enhancement of Tumor Growth: Two Animal Models Showing Amelioration by Leukodepletion and Passive Transfer Using Spleen Cells (1993) (92)
- New strategies for the optimal use of platelet transfusions. (2008) (92)
- Transfusion immunomodulation or TRIM: What does it mean clinically? (2005) (91)
- Allogeneic blood transfusion-induced enhancement of tumor growth: two animal models showing amelioration by leukodepletion and passive transfer using spleen cells. (1993) (91)
- Prevalence of antithrombin deficiency in healthy blood donors: A cross‐sectional study (1994) (90)
- Post-transfusion hepatitis: impact of non-A, non-B hepatitis surrogate tests (1995) (89)
- An animal model of allogeneic donor platelet refractoriness: the effect of the time of leukodepletion. (1992) (88)
- Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction. (2001) (87)
- Antithrombin-III-Hamilton: a gene with a point mutation (guanine to adenine) in codon 382 causing impaired serine protease reactivity. (1988) (84)
- Growth enhancement of established tumors by allogeneic blood transfusion in experimental animals and its amelioration by leukodepletion: the importance of the timing of the leukodepletion. (1994) (82)
- REVIEW OF THE CLINICAL PRACTICE LITERATURE ON ALLOGENEIC RED BLOOD CELL TRANSFUSION (1997) (81)
- Bacterial contamination of platelet concentrates: incidence, significance, and prevention. (2001) (81)
- Infectious disease testing for blood transfusions. (1995) (80)
- Mechanisms of transfusion-associated immunosuppression. (1994) (78)
- Incidence and significance of the bacterial contamination of blood components. (2002) (78)
- Avoiding Transfusions in Children Undergoing Cardiac Surgery: A Meta-Analysis of Randomized Trials of Aprotinin (2006) (76)
- Growth Enhancement of Established Tumors by Allogeneic Blood Transfusion in Experimental Animals and Its Amelioration by Leukodepletion: The Importance of the Timing of the Leukodepletion (1994) (74)
- Cytokeratin 18 Is Expressed on the Hepatocyte Plasma Membrane Surface and Interacts with Thrombin-Antithrombin Complexes* (1997) (74)
- Current Research on the Immunomodulatory Effect of Allogeneic Blood Transfusion (1996) (71)
- The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate (1985) (70)
- Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate. (1987) (69)
- The age of red blood cells in premature infants (ARIPI) randomized controlled trial: study design. (2009) (68)
- Clinical and molecular basis of transfusion-induced immunomodulation: summary of the proceedings of a state-of-the-art conference. (2001) (65)
- Severe factor VII deficiency caused by mutations abolishing the cleavage site for activation and altering binding to tissue factor. (1994) (65)
- A multicenter pilot‐randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation (2007) (65)
- Protecting the Blood Supply From Emerging Pathogens: The Role of Pathogen Inactivation (2005) (63)
- Prevalence of factor V Leiden in a Canadian blood donor population. (1996) (63)
- The first epidermal growth factor domain of human coagulation factor VII is essential for binding with tissue factor (1992) (59)
- An Antithrombin III Assay Based on Factor Xa Inhibition Provides a More Reliable Test to Identify Congenital Antithrombin III Deficiency Than an Assay Based on Thrombin Inhibition (1993) (58)
- Transfusion-related acute lung injury. (2003) (57)
- Molecular basis of inherited human antithrombin deficiency (1992) (55)
- Why implement universal leukoreduction? (2008) (55)
- Immunosuppressive effects of allogeneic blood transfusions: implications for the patient with a malignancy. (1995) (54)
- Addressing the risk of bacterial contamination of platelets within the United States: a history to help illuminate the future (2013) (52)
- The thrombocytopenic rabbit bleeding time model to evaluate the in vivo hemostatic efficacy of platelets and platelet substitutes. (1997) (50)
- Transient Donath‐Landsteiner Haemolytic Anaemia (1981) (49)
- Thrombosis in antithrombin‐III‐deficient persons. Report of a large kindred and literature review (1993) (48)
- Passive transfer of peanut hypersensitivity by fresh frozen plasma. (2007) (46)
- The Clearance of Thrombin-antithrombin and Related Serpin-enzyme Complexes from the Circulation: Role of Various Hepatocyte Receptors (1999) (46)
- Infectious disease testing for blood transfusions. NIH Consensus Development Panel on Infectious Disease Testing for Blood Transfusions. (1995) (45)
- The tumor growth-promoting effect of allogeneic blood transfusions. (1995) (45)
- Reducing the risk of bacterial contamination of cellular blood components. (2000) (44)
- Molecular analysis of glycophorin A and B gene structure and expression in homozygous Miltenberger class V (Mi. V) human erythrocytes. (1989) (44)
- In vivo recovery and survival of apheresis and whole blood‐derived platelets: a paired comparison in healthy volunteers (2006) (43)
- Transfusion‐related immunomodulation due to peripheral blood dendritic cells expressing the CD200 tolerance signaling molecule and alloantigen (2008) (42)
- The spectrum of ABO hemolytic disease of the newborn infant. (1979) (42)
- Canadian Red Cross Society symposium on leukodepletion: report of proceedings. (1994) (42)
- Prestorage versus poststorage white cell reduction for the prevention of the deleterious immunomodulatory effects of allogeneic blood transfusion. (2000) (41)
- Novel treatment modalities: new platelet preparations and subsititutes (2001) (41)
- Hypotensive transfusion reactions can occur with blood products that are leukoreduced before storage (2004) (40)
- Hemolytic and pseudo-hemolytic transfusion reactions: an overview of the hemolytic transfusion reactions and the clinical conditions that mimic them. (1994) (40)
- Severe hemolytic anemia post-renal transplantation produced by donor anti-D passenger lymphocytes: case report and literature review. (2009) (39)
- Assessment of the hemostatic effectiveness of human platelets treated with aminomethyltrimethyl psoralen and UV A light using a rabbit ear bleeding time technique. (1993) (39)
- Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of alpha-thrombin. (1992) (38)
- The inhibition by heparin of the intrinsic pathway activation of factor X in the absence of antithrombin-III. (1980) (37)
- Bacterial contamination of blood products and the value of pre-transfusion testing. (1995) (37)
- CD200-dependent and nonCD200-dependant pathways of NK cell suppression by human IVIG (2008) (37)
- The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor (1984) (35)
- Recombinant factor VIIa reduces bleeding in severely thrombocytopenic rabbits. (2003) (35)
- Transfusion‐associated bacterial sepsis: the phoenix rises yet again (1994) (35)
- Measurement of Markers of Activated Coagulation in Antithrombin III Deficient Subjects (1992) (34)
- A multidisciplinary “think tank”: the top 10 clinical trial opportunities in transfusion medicine from the National Heart, Lung, and Blood Institute–sponsored 2009 state‐of‐the‐science symposium (2011) (33)
- Pseudopolycythemia, pseudothrombocytopenia, and pseudoleukopenia due to overfilling of blood collection vacuum tubes. (1992) (33)
- Novel platelet products, substitutes and alternatives. (2001) (33)
- Proceedings of a consensus conference: Risk-Based Decision Making for Blood Safety. (2011) (33)
- Cellular immunocompetence in melanoma: effect of extent of disease and immunotherapy. (1975) (32)
- An approach to determine objectively minimum hemoglobin standards for blood donors (1985) (32)
- Age‐related changes in factor VII proteolysis in vivo (1996) (32)
- IMMUNOGLOBULINS IN WARM-TYPE AUTOIMMUNE HÆMOLYTIC ANÆMIA (1969) (31)
- The thrombogenicity of prothrombin complex concentrates: I. The relationship between in vitro characteristics and in vivo thrombogenicity in rabbits. (1980) (31)
- The amount of blood group A substance on platelets is proportional to the amount in the plasma (1982) (30)
- Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop (2009) (30)
- Substitutes for success (1999) (29)
- A proposal for an individual patient data based meta-analysis of randomized controlled trials of allogeneic transfusion and postoperative bacterial infection. (1997) (29)
- Defining the heparin-binding domain of antithrombin. (1994) (29)
- Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma. (1991) (29)
- Bacterial contamination of blood products. (2001) (29)
- Prostaglandin I2 (prostacyclin). (1980) (28)
- In Vivo Clearance of Ternary Complexes of Vitronectin-Thrombin-Antithrombin Is Mediated by Hepatic Heparan Sulfate Proteoglycans* (1998) (27)
- Landmark studies that have changed the practice of transfusion medicine (2005) (27)
- Plasma Anticoagulant Mechanisms of Heparin, Heparan Sulfate, and Dermatan Sulfate a (1989) (27)
- Incorporation of 7-deaza dGTP during the amplification step in the polymerase chain reaction procedure improves subsequent DNA sequencing. (1990) (27)
- Alloantibodies and platelet destruction. (1982) (26)
- Molecular cloning and expression of rabbit antithrombin III. (1992) (26)
- Clinical trial opportunities in Transfusion Medicine: proceedings of a National Heart, Lung, and Blood Institute State-of-the-Science Symposium. (2010) (26)
- The amount of blood group A substance on platelets is proportional to the amount in the plasma. (1982) (26)
- Extending the horizon for cell-based immunotherapy by understanding the mechanisms of action of photopheresis. (2010) (25)
- Immunomodulatory Effects of Blood Transfusion (1999) (25)
- transfusion and the available strategies for their prevention Transfusion-related mortality: the ongoing risks of allogeneic blood (2013) (24)
- Transfusion-related acute lung injury (2005) (24)
- Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma. (1982) (24)
- Novel platelet products and substitutes. (1998) (24)
- The isolation of prothrombin, Factor IX and Factor X from human Factor IX concentrates. (1984) (23)
- Regions Flanking Exon 1 Regulate Constitutive Expression of the Human Antithrombin Gene* (1996) (23)
- Proceedings of a consensus conference: the screening of blood donors for variant CJD. (2004) (22)
- Antithrombin-III-Hamilton, Ala 382 to Thr: an antithrombin-III variant that acts as a substrate but not an inhibitor of alpha-thrombin and factor Xa. (1991) (22)
- Risks associated with blood transfusion in newborn infants. (1984) (22)
- GUTI: a new antigen in the Cromer blood group system (2003) (22)
- An increased uptake of prothrombin, antithrombin, and fibrinogen by the rabbit balloon-deendothelialized aorta surface in vivo is maintained until reendothelialization is complete. (1996) (22)
- DIAGNOSTIC AMNIOCENTESIS AND FETAL-MATERNAL BLEEDING (1974) (21)
- Activation of factor X and prothrombin in antithrombin-III depleted plasma: the effects of heparin. (1981) (21)
- Quantitation of red cell membrane associated immunoglobulin in children with Plasmodium falciparum parasitaemia (1983) (21)
- Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and D-Phe-Pro-Arg-Ch2Cl. (1990) (21)
- Antithrombin-III-Stockholm: a codon 392 (Gly----Asp) mutation with normal heparin binding and impaired serine protease reactivity. (1992) (21)
- An Approach to Assigning In Vitro Potency to Unfractionated and Low Molecular Weight Heparins Based on the Inhibition of Prothrombin Activation and Catalysis of Thrombin Inhibition (1988) (21)
- A second example of a transfusion‐associated septic reaction associated with Clostridium perfringens (2001) (20)
- Transfusion-related immunosuppression (2009) (20)
- The role of red blood cell antigens, histocompatibility antigens, and blood transfusions on renal allograft survival. (1989) (20)
- o-raffinose cross-linked hemoglobin improves the hemostatic defect associated with anemia and thrombocytopenia in rabbits. (2000) (20)
- Platelet transfusions: an historical perspective. (2008) (19)
- Universal leucocyte‐depletion of blood components: cell concentrates and plasma (2001) (19)
- Catabolism of rabbit prothrombin in rabbits: uptake of prothrombin by the aorta wall before and after a de-endothelializing injury in vivo. (1995) (19)
- Activation and Active Site Occupation Alter Conformation in the Region of the First Epidermal Growth Factor-like Domain of Human Factor VII* (2000) (19)
- Shortening of the bleeding time in thrombocytopenic rabbits after exposure of jugular vein to high aspirin concentration. (1979) (19)
- Expression and purification of recombinant rabbit factor VII. (2000) (18)
- A prospective study evaluating the lowering of hemoglobin standards for blood donors (1989) (18)
- The molecular pathology of inherited human antithrombin III deficiency. (1989) (18)
- Molecular basis of inherited human antithrombin deficiency. (1992) (18)
- Preparation and partial characterization of human plasma depleted of antithrombin-III by heparin-sepharose affinity chromatography. (1980) (18)
- Clinical use of blood, blood components and blood products. (1979) (17)
- Inhibition of factor X, factor V and prothrombin activation by the bis(lactobionic acid amide) LW10082. (1992) (17)
- Platelet substitutes and novel platelet products (2000) (17)
- The low molecular weight heparin Enoxaparin inhibits the consumption of factor VII and prothrombin activation in vivo associated with elective knee replacement surgery (1992) (17)
- Red blood cell transfusion strategies. (2001) (17)
- Immunodepletion of human plasma factor VIII. (1980) (17)
- Mutation of any site of N-linked glycosylation accelerates the in vivo clearance of recombinant rabbit antithrombin. (2000) (17)
- Envelope glycoprotein of avian hemangioma retrovirus induces a thrombogenic surface on human and bovine endothelial cells (1990) (17)
- Transfusion medicine--the coming of age of a new specialty. (1987) (16)
- Cytokines in transfusion medicine (1993) (16)
- Intracellular events determine the fate of antithrombin Utah. (1995) (16)
- Antithrombin III Sudbury: an Ala384----Pro mutation with abnormal thrombin-binding activity and thrombotic diathesis. (1990) (16)
- Effect of allogeneic blood transfusion on solid tumor growth and pulmonary metastases in mice (2005) (16)
- Molecular Cloning and Cell-Free Expression of Mouse Antithrombin III (1992) (16)
- Site‐directed mutagenesis of the P2 residue of human antithrombin (1994) (15)
- Looking back in anger: retrospection in the face of a paradigm shift. (1997) (15)
- Inhibition of arterial thrombosis and platelet function by nafazatrom. (1982) (15)
- INDUCTION OF ANTIIDIOTYPIC ANTIBODIES BY BLOOD TRANSFUSIONS: CHARACTERIZATION OF T CELL ALLOANTIGEN‐SPECIFIC RECEPTORS BY SERA FROM TRANSFUSED MICE (1986) (15)
- Complete nucleotide sequence of the cDNA encoding rabbit coagulation factor VII. (1993) (15)
- Fibrinogen catabolism within the procoagulant VX-2 tumor of rabbit lung in vivo: Effluxing fibrin(ogen) fragments contain antiangiogenic activity. (2004) (15)
- The Procoagulant State of the VX-2 Tumor in Rabbit Lung In Vivo (1999) (14)
- Evidence for an alternative mechanism of human platelet secretion involving peripheralization of secretory granules and formation of membrane-associated multivesicular structures. (1987) (14)
- An overview of the mechanism of action of antithrombin and its inherited deficiency states (1994) (14)
- Partial deletion of an antithrombin III allele in a kindred with a type 1 deficiency. (1992) (14)
- Factor VII deficiency caused by a structural variant N57D of the first epidermal growth factor domain. (1998) (14)
- Expression in a cell-free system of normal and variant forms of human antithrombin III. Ability to bind heparin and react with alpha-thrombin. (1990) (14)
- Neonatal cytomegalovirus infections: the relative role of neonatal blood transfusion and maternal exposure. (1984) (14)
- Deletion mutagenesis of heparin cofactor II: defining the minimum size of a thrombin inhibiting serpin (1995) (14)
- The incidence of post-transfusion hepatitis. (1993) (13)
- The effect of leukodepletion on allogeneic donor platelet survival and refractoriness in an animal model. (1991) (13)
- Amino acid substitutions of the P2 residue of human antithrombin that either enhance or impair function. (1994) (13)
- Comparative metabolism and distribution of rabbit heparin cofactor II and rabbit antithrombin in rabbits. (1997) (13)
- Analysis of a pregnancy‐screening and neonatal‐immunization program for hepatitis B in Hamilton, Ontario, Canada, 1977‐1988 (1991) (13)
- Transfusion Microbiology: Bacterial contamination in blood and blood components (2008) (12)
- Noninfectious adverse effects of blood transfusion in the neonate. (1995) (12)
- The thrombogenicity of prothrombin complex concentrates: III. The relationship of in vivo thrombogenicity to the nature of the starting plasma. (1981) (12)
- Enhanced prothrombin‐converting activity and factor Xa binding of platelets activated by the alternative complement pathway (1984) (12)
- Trinucleotide repeat polymorphism within the human antithrombin gene (AT3): allele frequency data for three population groups. (1994) (12)
- Inhibition of factor X and factor V activation by dermatan sulfate and a pentasaccharide with high affinity for antithrombin III in human plasma. (1990) (12)
- Molecular Cloning and Expression of Rabbit Heparin Cofactor II: A Plasma Thrombin Inhibitor Highly Conserved between Species (1994) (12)
- HLA-A,B,C and B-lymphocyte alloantigens in insulin-dependent diabetes. (1977) (11)
- Association of renal failure with Lewis incompatibility after allogeneic bone marrow transplantation. (1985) (11)
- Do surrogate tests improve the safety of the blood supply? (1995) (11)
- The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop (2012) (11)
- Anti-idiotypic antibodies and suppressor cells in patients receiving pretransplant donor-specific blood transfusions. (1987) (10)
- Bacterial contamination of cellular blood products: the Canadian perspective. (2000) (10)
- Production in vitro of antibodies directed against alloantigen-specific recognition sites on T cells and on lymphocytotoxic HLA antibodies. (1988) (10)
- Effects of methyl prednisolone on platelet adhesion to damaged aorta bleeding time and platelet survival (1976) (10)
- Agreement study between two laboratories of immunofluorescence as a confirmatory test for human immunodeficiency virus type 1 antibody screening (1989) (10)
- Site‐directed mutagenesis of alanine‐382 of human antithrombin III (1991) (10)
- Angiostatin II is the predominant glycoform in pleural effusates of rabbit VX-2 lung tumors. (2002) (10)
- Consumption of plasma factor VII in a rabbit model of non-overt disseminated intravascular coagulation. (2002) (10)
- Research Ethics Boards: The Protection of Human Subjects (2006) (10)
- Letter: HL-A antigens in malignant melanoma. (1974) (10)
- ABO haemolytic disease of the new born. (1979) (9)
- Immunoglobulins in warm-type autoimmune haemolytic anaemia. (1969) (9)
- Molecular genetic basis for the antiidiotypic antibody response associated with successful renal allograft survival in humans. (1991) (8)
- CHAPTER 70 – Platelet Substitutes and Novel Methods of Platelet Preservation (2007) (8)
- The role of the complement system in hemostasis. (1986) (8)
- Metabolism of rabbit plasma-derived factor VII in relation to prothrombin in rabbits. (2001) (8)
- Rapid in vivo induction of leukocyte tissue factor mRNA and protein synthesis following low dose endotoxin administration to rabbits. (2001) (8)
- The direct binding of human factor VII in plasma to recombinant human tissue factor. (1993) (8)
- Role of the ABO, Secretor, and Lewis determinants in the primed lymphocyte test. (1981) (8)
- A novel congenital haemostatic defect: combined factor VII and factor XI deficiency (1992) (8)
- Arginine-79 in the first epidermal growth factor domain of factor VII is essential for the interaction with tissue factor. (1993) (8)
- Immunomodulatory and Proinflammatory Effects of Allogeneic Blood Transfusion (2009) (8)
- Tissue antibodies in idiopathic autoimmune haemolytic anaemia. (1971) (7)
- Effects of heparin fractions of different affinities to antithrombin III and thrombin on the inactivation of thrombin and factor Xa by antithrombin III. (1984) (7)
- Substitution of the “group-and-screen” for the full crossmatch in elective operations (1983) (7)
- The thrombogenicity of prothrombin complex concentrates: II. The effect of thrombocytopenia on in vivo thrombogenicity in rabbits. (1980) (7)
- Blood transfusion : a conceptual approach (1984) (6)
- Antithrombin III‐Amiens: A new family with an Arg47 → cys inherited variant of antithrombin iii with impaired heparin cofactor activity (1991) (6)
- Uptake of heparin cofactor II and antithrombin into the aorta wall after a deendothelializing injury in vivo: comparison with the behaviors of prothrombin and fibrinogen. (1999) (6)
- Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival. (1977) (6)
- The N-terminal domain of antithrombin-III is essential for heparin binding and complex-formation with, but not cleavage by, alpha-thrombin. (1992) (6)
- HLA-restricted lymphoproliferative responses to MN blood group determinants (1982) (5)
- Molecular analysis of the HLA-D region and the T-cell antigen receptor beta-chain genes in monozygotic twins discordant for rheumatoid arthritis. (1989) (5)
- A novel and de novo spontaneous point mutation (Glu271STOP) of the antithrombin gene results in a type I deficiency and thrombophilia (1999) (5)
- Transfusion-related issues in Jehovah's Witness patients. (1991) (5)
- Activation of a recombinant human factor VII structural analogue alters its affinity of binding to tissue factor (1996) (5)
- Pioneers and Pathfinders in Transfusion Medicine (2005) (5)
- Impact of mutations at the P4 and P5 positions on the reaction of antithrombin with thrombin and elastase. (1997) (5)
- Randomized trials in patients with blunt and penetrating trauma. (2006) (4)
- Treatment of T. cruzi infected human platelet concentrates with aminomethyltrimethyl psoralen (AMT) and ultraviolet A (UV-A) light: preliminary results. (1996) (4)
- The Pathogen Inactivation of Platelets: Studies of the Possible Mechanisms of the Platelet Dysfunction Seen Following Photochemical Treatment. (2006) (4)
- Understanding the polymerase chain reaction. (1994) (4)
- Letter: Diagnostic amniocentesis and fetal-maternal bleeding. (1974) (4)
- Analysis of a Pregnancy-screening and Neonatal-immunization Program for Hepatitis B in Hamilton, Ontario, Canada, 1977–1988 (1992) (4)
- Blood component therapy in anaesthetic practice. (1983) (3)
- Defining transfusion medicine. (1990) (3)
- Bacterial Contamination of Blood Components (2000) (3)
- The factor VIII-independent activation of factor X by factors IXa and VII in plasma. (1981) (3)
- Approaches to the measurement of the in vivo response to factor VIII concentrate infusion. (1985) (3)
- Factor V deficiency and its reversal with gluten restriction. In a patient with celiac disease. (1983) (3)
- The in Vivo Evaluation of the Hemostatic Function of Stored Human Platelets (1977) (3)
- Antiidiotypic antibodies: production in vitro by EBV-transformed lymphoblastoid cell lines and immunochemical characterization of idiotypic receptors on T-cells. (1989) (3)
- Platelet substitutes. (2000) (3)
- The blood transfusion effect: characterization of T cell alloantigen-specific receptors by sera from transfused mice. (1987) (3)
- Chapter 47 – Bacterial Infections: Bacterial Contamination, Testing, and Post-Transfusion Complications (2007) (3)
- Abstract Presentations from the AABB Annual Meeting Philadelphia, PA, October 25‐28, 2014 (2014) (3)
- Non-HLA antigens in the primed lymphocyte test (PLT): responses to Lewis determinants. (1981) (3)
- Definition of transfusion medicine (2002) (2)
- HLA-restricted responses to M and N determinants in the primed lymphocyte test. (1981) (2)
- Transfusion Requirements in Critical Care (2017) (2)
- A useful restriction analysis for the determination of human antithrombin III variants with mutations from Ala 382 to Ala 384. (1992) (2)
- The Antithrombotic Properties of Human Prothrombin Fragment 1.2 in Mice (1990) (2)
- Characterization of a highly polymorphic trinucleotide short tandem repeat within the human antithrombin gene. (1994) (2)
- The Clinical Relevance and Biological Effects of Leukocytes Present in Cellular Blood Components (1996) (2)
- Transfusion‐Related Immunomodulation (TRIM) (2003) (2)
- Microheterogeneity of antithrombin III: effect of single amino acid substitutions and relationship with functional abnormalities (1994) (2)
- Clinical trial opportunities in hemostasis and thrombosis: NHBLI State‐of‐the‐science symposium (2012) (2)
- Comparative catabolism of prothrombin and antithrombin in normal and alloxan-diabetic rabbits. (1997) (2)
- Human Factor VIIai(K62E) Is a More Effective Inhibitor of Coagulation Than Wild-Type FVIIai. (2005) (2)
- Human Factor VIIai(K62E) Is a More Effective Inhibitor of Coagulation Than Wild-Type FVIIai. (2005) (2)
- Rifampicin-induced ImmuneThrombocytopenia (1970) (1)
- Thrombosis in Antithrombin-III-deficient Persons (2020) (1)
- Clinical Trial Opportunities in Transfusion Medicine: Proceedings of a National Heart, Lung, and Blood Institute State-of the-Science Symposium, 24/4 (October 2010) pp. 259-285 (2011) (1)
- CHAPTER 33 – Animal Models (2007) (1)
- Blood substitutes--a misnomer, nevertheless a promise. (1982) (1)
- Requirement of Factor VIII for the Generation of Xa in a Purified System and in Plasma. (1979) (1)
- Platelet refractoriness and alloimmunization are not necessarily synonymous (1994) (1)
- 270 A Randomized Controlled Trial of Low vs High Hemoglobin Thresholds for Transfusion in Extremely Low-Birth-Weight Infants (2004) (1)
- Platelet transfusions. (1979) (1)
- Blood Transfusion and Tumor Growth: Studies in Aimal Models (2017) (1)
- Panel Discussion: Rationale for replacement therapy for acquired antithrombin III deficiency (1994) (1)
- Evidence for independent pathways for the induction of platelet prothrombin-converting activity by thrombin and collagen. (1984) (1)
- Placebo tribulations. (2002) (1)
- Mini-symposium: The Role of Granulocytes in Transfusion Medicine (1990) (1)
- Prostaglandin I2 (prostacycin) (2006) (1)
- Molecular Defects in Human Antithrombin III Deficiency (1991) (1)
- Michael S. Murphy and Derwood H. Pamphilon, Editors, Practical Transfusion Medicine, Blackwell Science, Oxford UK (2001). (2002) (0)
- 新鲜冰冻血浆引发花生过敏被动转移 (2008) (0)
- Agreement Studybetween TwoLaboratories ofImmunofluorescence as a Confirmatory TestforHumanImmunodeficiency VirusType1 Antibody Screening (1989) (0)
- Comparative behavior of prothrombin and fibrinogen at the injured (de-endothelialized) aorta wall of the rabbit in vivo (1994) (0)
- Bacterial Contamination of Blood Components (2000) (0)
- Role of secretor and lewis antigens in Primed Lymphocyte Test (PLT) (1980) (0)
- Efficacy of leukodepletion filters in removing T. cruzi from contaminated blood. (1994) (0)
- ENTERAL HYPERALIMENTATION WITH CHEMICALLY DEFINED (2006) (0)
- AbstractIn vitro production of antiidiotypic antibodies by EBV-transformed B cell lines from renal transplant recipients (1988) (0)
- Chronic Sirolimus Therapy for Lymphangioleiomyomatosis (2014) (0)
- The Use of Aprotinin to Reduce Transfusion Requirements in Children Undergoing Cardiac Surgery: A Meta-Analysis. (2004) (0)
- of the time of leukodepletion An animal model of allogeneic donor platelet refractoriness: the effect (2011) (0)
- Chapter 51 – Transfusion-Related Acute Lung Injury (2007) (0)
- Blood transfusion, anesthesia, and host defense. (1990) (0)
- A Multicenter, Randomized, Controlled Clinical Pilot Trial of the Feasibility of an Intensive RBC Transfusion Policy for Patients with Acute Leukemia Treated with Induction Chemotherapy or Stem Cell Transplant. (2005) (0)
- Scientific Section (2012) (0)
- Molecular Cloning and Expression of Rabbit Antithrombin I11 (2003) (0)
- A Human Lymphoblastoid Cell Line Secreting Antiidiotypic Antibodies (1989) (0)
- adenine) in codon 382 causing impaired serine protease reactivity Antithrombin-III-Hamilton: a gene with a point mutation (guanine to (2011) (0)
- BREAST CANCER IN OLD AGE (1970) (0)
- activity in plasma by complementary pathways Heparan sulfate and dermatan sulfate inhibit the generation of thrombin (2011) (0)
- A Comparison of Two Assays for Platelet Antibodies (1979) (0)
- iscritical totheexpression oftheanticoagulant effect ofheparin (1987) (0)
- Age-related increases in factor VII proteolysis and tissue factor pathway inhibitor (1996) (0)
- Cumulative risks of early red blood cell transfusion (2006) (0)
- Clinical Effects of the Immunomodulation Associated with Allogeneic Blood Transfusions (2001) (0)
- Association of Renal Failure With Lewis Incompatibility After Allogeneic Bone Marrow Transplantation (1985) (0)
- The Hemostatic Response to Arterial Injury in Vivo : Behavior of Prothrombin at the De-Endothelialised Aorta Wall (1995) (0)
- Use of Plasma Segments for Estimating Factor VIII Activity in Pools of Fresh Frozen Plasma (1987) (0)
- A.M.A. EXTRAORDINARY GENERAL MEETING (1970) (0)
- Press Review (1999) (0)
- RIFAMPICIN AND THROMBOCYTOPENIA (1970) (0)
- Human FVII(K62E) does not exhibit enhanced binding to tissue factor (2008) (0)
- Hepatitis B surveillance. (1983) (0)
- 9 Premature Infants in Need of Transfusion – The Pint Study: A Multicentre International Randomized Trial of Blood Transfusion in ELBW Infants (2004) (0)
- An Animal Model Suitable for Predicting In Vivo Behavior of Platelets in Humans: A Tool for New Product Development. (2004) (0)
- The Mechanism of Transfusion-Related Immunomodulation Is Related to the Transfusion of Dendritic Cells Expressing the CD200 (OX-2) Tolerance Signal and Alloantigen: Evidence from a Murine Tumor Model. (2004) (0)
- Nucleotide sequences of an antiidiotypic antibody from a transplant recipient (2004) (0)
- Transfusion‐Associated Septic Reactions (2002) (0)
- Frequent association of factor VII defects with other clotting disorders (1992) (0)
- The N-terminal domain of antithrombin-III is essential for heparin binding and complex-formation with , but not cleavage by , cx-thrombin (2005) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Morris A. Blajchman?
Morris A. Blajchman is affiliated with the following schools: